We're heading to @AASLDtweets The Liver Meeting 2026 in Denver, November 5 to 9. Eleven members of the Perspectum team will be at #TLM26, presenting five posters and one oral presentation. You'll find us at booth #1055. For clinicians: see how LiverMultiScan supports non-invasive liver health assessment, with quantified metrics for liver disease activity (cT1), liver fat fraction (PDFF) and liver iron concentration to inform clinical decisions across diagnosis, treatment and monitoring. For pharma and clinical development teams: talk to us about quantitative liver imaging biomarkers in liver disease trials, from screening and enrichment through to measuring change over time. To book time with the team at the booth, email Pharma.Business[email protected]. We'll share more on what we're presenting in the coming weeks. #Perspectum #AASLD #TLM26 #Hepatology #LiverDisease

Cardiovascular, kidney, liver and metabolic disease rarely develop in isolation. So how do you design a single trial that captures endpoints across all of them? That question sits at the heart of MOSAIC 2026, the multi-specialty trialists' forum on cardio-kidney-liver-metabolic (CKLM) disease. Perspectum is a proud sponsor of this year's meeting, and our team will be in the room. On Monday, October 26, Andrea Dennis, SVP Translational Science, speaks in the session "How to design a single trial with multiple CKLM endpoints? Methodology and statistical toolkits." Multi-organ imaging. The UK Imaging Diabetes Study 4:00–4:10 pm ET Andrea will be joined by Carlos Duncker, Senior Medical Director. If you're attending, they'd welcome a conversation on endpoints, imaging and trial design. For those designing CKLM trials: which endpoint is hardest to align across specialties? #Perspectum #MASH #ClinicalTrials

Crypt epithelium neutrophil density was 4.6-fold higher in endoscopically active UC than in remission, by AI histology. Dylan Windell presents at @my_ueg Week, Tue 20 Oct, Hall 7, from 08:54 CEST; Reema Kainth has our spatial ePoster. #Perspectum #UEGWeek2026

In 72 pediatric autoimmune liver disease patients, plasma bile acids tracked with quantitative MRCP+ measures of bile duct dilation. Routine labs did not. Cincinnati Children's poster P6273, Tue Oct 13, 10:30–4:00 CT, presented by Thuy Nguyen. #Perspectum #ACG2026

Perspectum is at ASN #KidneyWk 2026 in Denver, 21–25 Oct. Caitlin Langford, Senior Director of Product, is meeting pharma and research teams to discuss quantitative MRI in renal drug development. Working on kidney trials? Come and find us. #Perspectum #Nephrology

Alone, cT1, liver fat and spleen volume identified cirrhosis in MASLD with AUC 0.66 to 0.72. Combined: 0.87 (test cohort 0.85). Michele Pansini presents this poster at the Society for Advanced Body Imaging 2026, 13th October. Find him there or at our tabletop. #Perspectum #MASLD

Perspectum is at UEG Week 2026 in Barcelona, 17 to 20 October, with Marija Mavar, Reema Kainth, Nicholas Hyde and Dylan Windell. Working in IBD trials or GI pathology? Come and find us. #Perspectum #UEGWeek #IBD

Metabolic disease rarely affects only one organ. So how do you capture a therapy's effects beyond its target organ in trial design? Thursday 15 October, #ELRIGDD26: Anna Veprik presents how multi-organ MR imaging can be used as a precision biomarker in drug discovery. #Perspectum #DrugDiscovery

"Objective, reproducible measurements we can follow over time." That's how Dr Steven Tucker of Tucker Medical, Singapore, describes Perspectum's quantitative MRI, now part of the practice's preventive and survivorship care. Read the full announcement: perspectum.com/tucker-medica… #Perspectum #QuantitativeMRI

Perspectum is a Bronze Sponsor at SABI 2026, 11 to 14 Oct, Savannah GA. Michele Pansini and Balaji Ganeshan will be at our tabletop in the exhibit area to talk quantitative liver MRI and where it fits in body imaging workflows. Come and say hello. #Perspectum #SABI2026

Heading to #ACG2026 in Nashville, Oct 9–14? Thuy Nguyen, VP US Medical Affairs and Prashant Pandya, Medical Director, are there all week to talk quantitative MRI in liver disease.

Best Poster at the 12th Paris MASH Meeting went to our digital pathology team. Congratulations to lead author Dylan Windell and everyone behind the work! MASH is a form of steatotic liver disease, where fat build-up comes with inflammation and liver damage. Trials of new MASH treatments depend on pathologists scoring liver biopsy slides. So the team asked a simple question: do AI measurements agree with what the experts see? In biopsy slides from 156 people with MASLD or MASH, PAIR™ MASH measurements agreed with scores from two expert pathologists: fibrosis (scarring, rho 0.78), fat (rho 0.67), ballooning (rho 0.62) and inflammation (rho 0.41). Many people know us for imaging. Fewer know we also have a experienced pathology team that provides central histology reads for over 10 active phase 2 and 3 clinical trials. There's more to come at The Liver Meeting in November. #Perspectum #MASH #DigitalPathology#Perspectum #MASH #DigitalPathology

Cardiovascular disease rarely occurs on its own. It develops alongside the conditions that influence it: type 2 diabetes, obesity, high blood pressure, and liver fat that accumulates silently for years. That is why cardiovascular risk is increasingly understood as cardiometabolic risk. People living with MASLD (metabolic dysfunction-associated steatotic liver disease), for example, carry a higher risk of cardiovascular disease. The information that matters for the heart may not always be found in the heart alone. This World Heart Day, look at the whole system, not one organ. At Perspectum, we build quantitative imaging technology for exactly this: a whole-system view of cardiometabolic health. #Perspectum #WorldHeartDay #CardiometabolicHealth #HeartHealth #LiverHealth

The fat your BMI does not show. In 75,331 UK Biobank participants, people with more visceral fat on MRI were more likely to develop type 2 diabetes, independent of BMI. A single L3 slice showed a similar association to the whole-abdomen measurement. Presented at EASD 2026, Tue 30 Sep, 11:45 CEST.

Heading to GHAPP in Chula Vista, 1 to 3 October? So are we. Perspectum is a Bronze Sponsor, and Dr Prashant Pandya and Jill Rizer will be there all three days. NPs and PAs in GI or hepatology: come and talk MRI-based liver assessment. #Perspectum #GHAPP2026

Two patients can lose the same amount of weight and end up in very different physiological states. One loses visceral and ectopic fat. The other loses skeletal muscle. We integrate MRI body composition into obesity and cardiometabolic trials to characterise the quality of weight loss. Meet us at EASD 2026, Milan, 28 Sept to 2 Oct. perspectum.com/pharma/body-c… #Perspectum

Perspectum has appointed Warren Cresswell as Chief Executive Officer, effective 15 September 2026. He brings more than 25 years in life sciences, much of it leading diagnostics businesses. Read the announcement: pulse.ly/1r84lhvvcu #Perspectum

We are proud to announce that Principal Cardiovascular Scientist Masliza Mahmod was awarded Fellow of the European Society of Cardiology (FESC) in Munich, pictured here with Prof Marco Roffi, ESC Vice President. The Fellowship recognises the highest professional standards and commitment to reducing the burden of cardiovascular disease, alongside sustained contribution to the Society. Masliza has spent her career in cardiovascular medicine, research and imaging, with particular expertise in cardiac and metabolic imaging. Seeing that recognised by her peers meant a great deal to all of us. #Perspectum #ESCCongress #Cardiology #CVRM #ClinicalTrials #CardiacMRI

What can a single scan tell us about liver health in cancer surveillance? Quantitative MRI (qMRI) has been studied extensively in Western cohorts, but until now, there has been limited evidence of its use in surveillance of hepatocellular carcinoma (HCC), which is more prevalent in Asian populations. Results from the imaging arm of the ELEGANCE study were recently published in BMC Gastroenterology and reported on 769 participants with chronic liver disease who underwent HCC surveillance in Singapore. What did the scans show? In patients with Hepatitis B, Perspectum's qMRI identified concurrent steatotic liver disease in more than 40% of participants In patients with metabolic dysfunction associated steatotic liver disease (MASLD) , Perspectum's qMRI suggested 31% also had metabolic dysfunction associated steatohepatitis (MASH) – a more active form of the disease with liver inflammation and injury Across patients with different underlying causes of liver disease, cirrhosis was associated with elevated iron-corrected T1, reduced liver fat, spleen enlargement and caudate hypertrophy. When these imaging features were combined, they were able to identify the patients with cirrhosis in the MASLD cohort (AUC 0.88) Importantly, an exploratory analysis found that the same imaging could distinguish participants who would go on to receive a HCC diagnosis from those who did not. Why does this matter? A single non-contrast MRI scan could provide a much richer picture of your liver health. It can characterise disease activity, fat, iron and organ structure. These measurements can help clinicians better understand disease burden, and could potentially identify which people need closer monitoring for liver cancer. Led by Yi-Chun Wang and Yu Jun Wong, with the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group. With thanks to the full author team: Yi-Chun Wang, Yu Jun Wong, Edward Jackson, Andrea Dennis, Sophie Riddell, Oi Fong Chong, Jeremy Wei Song Choo, Sulaiha Binte Ithnin, Pik Eu Jason Chang, Guan Huei Lee, Marianne Anastasia De Roza, Kalki R Chandrasekaran, Kok Kiong Ong, Patricia Ching Yen Chia, Kee Tung Tan, Ngiap Chuan Tan, Wei Lyn Yang, Xin Yi Yeap, Han Chong Toh, Cheryl Min En Chua, Jacelyn Siou Sze Chua, Jade Shu Qi Goh, Yu Ki Sim, Xin Hui Rachel Teo, Michael Brady and Pierce Kah Hoe Chow. Read the paper: bmcgastroenterol.biomedcentr… #Perspectum #Hepatology #HCC #MASLD #HepatitisB #LiverHealth #QuantitativeMRI

Three posters at the 12th Paris MASH Meeting, Institut Pasteur, 10–11 September. Alcohol exposure and liver iron. Where fat sits in cirrhosis. Continuous histology measurements against expert scoring. Presented by Andrea Dennis, 10 September. #Perspectum #MASH